Accumulating evidence shows that the beneficial actions of DPP4 inhibition (i.e., antiapoptosis, antioxidative stress, and anti-inflammation) are most likely partially responsible for the multiple pleotropic effects targeting the metabolic and atherosclerosis-based cardiovascular disorders addressed by this class of agents [2–5,8,15–17]. Here, DPP4 is linked to atherosclerosis.